Skip to main content
Erschienen in: Rheumatology International 9/2018

19.07.2018 | Review

Rheumatology science and practice in India

verfasst von: Durga Prasanna Misra, Aman Sharma, Vikas Agarwal

Erschienen in: Rheumatology International | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

The practice of rheumatology in a country like India presents its own unique challenges, including the need to manage patients in a cost-constrained setting, where the lack of uniform government funding for healthcare merits the need to optimize the use of cheaper medicines, as well as devise innovative strategies to minimize the use of costlier drugs such as biologic disease-modifying agents. Use of immunosuppressive agents is also associated with increased risks of infectious complications, such as the reactivation of tuberculosis. In this narrative review, we provide a flavor of such challenges unique to Rheumatology practice in India, and review the published literature on the management of common rheumatic diseases from India. In addition, we critically review existing guidelines for the management of rheumatic diseases from this part of the world. We also discuss infectious etiologies of rheumatic complaints, such as leprosy, tuberculosis, and Chikungunya arthritis, which are often encountered here, and pose a diagnostic as well as therapeutic challenge for clinicians. There remains a need to identify and test more cost-effective strategies for Indian patients with rheumatic diseases, as well as the requirement for more government participation to enhance scant facilities for the treatment of such diseases as well as foster the development of healthcare services such as specialist nurses, occupational therapists and physiotherapists to enable better management of these conditions.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
10.
Zurück zum Zitat Smolen JS, Landewé R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977PubMedCrossRef Smolen JS, Landewé R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977PubMedCrossRef
12.
Zurück zum Zitat Bhati M, Bandyopadhyay S (2016) Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs. Clin Rheumatol 35:1931–1935. https://doi.org/10.1007/s10067-016-3332-8 PubMedCrossRef Bhati M, Bandyopadhyay S (2016) Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs. Clin Rheumatol 35:1931–1935. https://​doi.​org/​10.​1007/​s10067-016-3332-8 PubMedCrossRef
13.
Zurück zum Zitat Malaviya AN, Gogia SB (2016) Treatment of rheumatoid arthritis (RA) in India—how and by whom: results from a speciality clinic—use of low-dose methotrexate (MTX) was inexplicably suboptimal. Clin Rheumatol 35:2163–2173PubMedCrossRef Malaviya AN, Gogia SB (2016) Treatment of rheumatoid arthritis (RA) in India—how and by whom: results from a speciality clinic—use of low-dose methotrexate (MTX) was inexplicably suboptimal. Clin Rheumatol 35:2163–2173PubMedCrossRef
17.
Zurück zum Zitat Pandya S, Aggarwal A, Misra R (2002) Methotrexate twice weekly vs once weekly in rheumatoid arthritis: a pilot double-blind, controlled study. Rheumatol Int 22:1–4PubMedCrossRef Pandya S, Aggarwal A, Misra R (2002) Methotrexate twice weekly vs once weekly in rheumatoid arthritis: a pilot double-blind, controlled study. Rheumatol Int 22:1–4PubMedCrossRef
20.
Zurück zum Zitat Chopra A, Lavin P, Patwardhan B, Chitre D (2000) Randomized double blind trial of an ayurvedic plant derived formulation for treatment of rheumatoid arthritis. J Rheumatol 27:1365–1372PubMed Chopra A, Lavin P, Patwardhan B, Chitre D (2000) Randomized double blind trial of an ayurvedic plant derived formulation for treatment of rheumatoid arthritis. J Rheumatol 27:1365–1372PubMed
21.
Zurück zum Zitat Chopra A, Saluja M, Tillu G et al (2012) Comparable efficacy of standardized ayurveda formulation and hydroxychloroquine sulfate (HCQS) in the treatment of rheumatoid arthritis (RA): a randomized investigator-blind controlled study. Clin Rheumatol 31:259–269PubMedCrossRef Chopra A, Saluja M, Tillu G et al (2012) Comparable efficacy of standardized ayurveda formulation and hydroxychloroquine sulfate (HCQS) in the treatment of rheumatoid arthritis (RA): a randomized investigator-blind controlled study. Clin Rheumatol 31:259–269PubMedCrossRef
25.
Zurück zum Zitat van der Heijde D, Ramiro S, Landewé R et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76:978–991PubMedCrossRef van der Heijde D, Ramiro S, Landewé R et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76:978–991PubMedCrossRef
27.
Zurück zum Zitat Sandhya P, Danda D, Mathew J, Gattani A (2011) Outcome of patients with seronegative spondyloarthritis continuing sulphasalazine and methotrexate after a short course of infliximab therapy—experience from a tertiary care teaching hospital in South India. Clin Rheumatol 30:997–1001. https://doi.org/10.1007/s10067-011-1723-4 PubMedCrossRef Sandhya P, Danda D, Mathew J, Gattani A (2011) Outcome of patients with seronegative spondyloarthritis continuing sulphasalazine and methotrexate after a short course of infliximab therapy—experience from a tertiary care teaching hospital in South India. Clin Rheumatol 30:997–1001. https://​doi.​org/​10.​1007/​s10067-011-1723-4 PubMedCrossRef
29.
Zurück zum Zitat Santra G, Sarkar RN, Phaujdar S, Banerjee S, Siddhanta S (2010) Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial. Singap Med J 51:883–887 Santra G, Sarkar RN, Phaujdar S, Banerjee S, Siddhanta S (2010) Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial. Singap Med J 51:883–887
32.
Zurück zum Zitat Malaviya AN, Kapoor S, Garg S, Ahmad I, Raja RR (2007) A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. J Assoc Physicians India 55:193–197PubMed Malaviya AN, Kapoor S, Garg S, Ahmad I, Raja RR (2007) A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. J Assoc Physicians India 55:193–197PubMed
35.
Zurück zum Zitat Grover R, Kapoor S, Marwaha V et al (2005) Clinical experience with infliximab in spondyloarthropathy: an open label study on fourteen patients. J Indian Rheumatol Assoc 13:78–82 Grover R, Kapoor S, Marwaha V et al (2005) Clinical experience with infliximab in spondyloarthropathy: an open label study on fourteen patients. J Indian Rheumatol Assoc 13:78–82
36.
Zurück zum Zitat (2011) Risk of infection during biologic therapy in rheumatic diseases: five years experience in a tertiary care hospital. Indian J Rheumatol 6:113–114 (2011) Risk of infection during biologic therapy in rheumatic diseases: five years experience in a tertiary care hospital. Indian J Rheumatol 6:113–114
37.
Zurück zum Zitat Malaviya A, Haroon N (2011) Infections associated with the use of biologic response modifiers in rheumatic diseases: a critical appraisal. Indian J Rheumatol 6:99–112CrossRef Malaviya A, Haroon N (2011) Infections associated with the use of biologic response modifiers in rheumatic diseases: a critical appraisal. Indian J Rheumatol 6:99–112CrossRef
38.
Zurück zum Zitat Fernandes L, Hagen KB, Bijlsma JWJ et al (2013) EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis 72:1125–1135PubMedCrossRef Fernandes L, Hagen KB, Bijlsma JWJ et al (2013) EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis 72:1125–1135PubMedCrossRef
39.
Zurück zum Zitat Das SK, Ramakrishnan S, Mishra K et al (2002) A randomized controlled trial to evaluate the slow-acting symptom-modifying effects of colchicine in osteoarthritis of the knee: a preliminary report. Arthritis Rheum 47:280–284PubMedCrossRef Das SK, Ramakrishnan S, Mishra K et al (2002) A randomized controlled trial to evaluate the slow-acting symptom-modifying effects of colchicine in osteoarthritis of the knee: a preliminary report. Arthritis Rheum 47:280–284PubMedCrossRef
40.
42.
44.
Zurück zum Zitat Pareek A, Gupta AK, Chandurkar NB et al (2011) Zaltoprofen, a noninferior alternative to diclofenac for the treatment of primary knee osteoarthritis—a comparative evaluation of efficacy and safety in a 4-week, multicentric, randomized, double-blind, double-dummy trial. Expert Opin Pharmacother 12:1007–1015. https://doi.org/10.1517/14656566.2011.566867 PubMedCrossRef Pareek A, Gupta AK, Chandurkar NB et al (2011) Zaltoprofen, a noninferior alternative to diclofenac for the treatment of primary knee osteoarthritis—a comparative evaluation of efficacy and safety in a 4-week, multicentric, randomized, double-blind, double-dummy trial. Expert Opin Pharmacother 12:1007–1015. https://​doi.​org/​10.​1517/​14656566.​2011.​566867 PubMedCrossRef
45.
Zurück zum Zitat Srikanth, Shah HM, Shivamurthy MC, Niveditha (2012) A comparative study of efficacy and tolerability of dexketoprofen trometamol versus diclofenac sodium in the symptomatic treatment of knee osteoarthritis. Pharmacologyonline 3:50–57 Srikanth, Shah HM, Shivamurthy MC, Niveditha (2012) A comparative study of efficacy and tolerability of dexketoprofen trometamol versus diclofenac sodium in the symptomatic treatment of knee osteoarthritis. Pharmacologyonline 3:50–57
51.
Zurück zum Zitat Bertsias GK, Tektonidou M, Amoura Z et al (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771–1782PubMedPubMedCentralCrossRef Bertsias GK, Tektonidou M, Amoura Z et al (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771–1782PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Malaviya AN, Singh RR, Sindhwani R et al (1992) Intermittent intravenous pulse cyclophosphamide treatment in systemic lupus erythematosus. Indian J Med Res 96:101–108PubMed Malaviya AN, Singh RR, Sindhwani R et al (1992) Intermittent intravenous pulse cyclophosphamide treatment in systemic lupus erythematosus. Indian J Med Res 96:101–108PubMed
57.
Zurück zum Zitat Boumpas DT, Austin HA III, Vaughn EM et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745PubMedCrossRef Boumpas DT, Austin HA III, Vaughn EM et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745PubMedCrossRef
59.
Zurück zum Zitat Gupta V, Edavalath S, Rai MK et al (2017) Tacrolimus induces remission in refractory and relapsing lupus nephritis by decreasing P-glycoprotein expression and function on peripheral blood lymphocytes (abstract). Arthritis Rheumatol 69(suppl 10):2787–2788 Gupta V, Edavalath S, Rai MK et al (2017) Tacrolimus induces remission in refractory and relapsing lupus nephritis by decreasing P-glycoprotein expression and function on peripheral blood lymphocytes (abstract). Arthritis Rheumatol 69(suppl 10):2787–2788
63.
Zurück zum Zitat Agarwal V, Ghosh P, Sharma A et al Efficacy of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study (abstract). Arthritis Rheum 62 (suppl 10):2086 Agarwal V, Ghosh P, Sharma A et al Efficacy of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study (abstract). Arthritis Rheum 62 (suppl 10):2086
64.
Zurück zum Zitat Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327–1339PubMedCrossRef Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327–1339PubMedCrossRef
67.
69.
Zurück zum Zitat Sharma BK, Jain S, Suri S, Numano F (1996) Diagnostic criteria for Takayasu arteritis. Int J Cardiol 54(Suppl): S141–S147PubMedCrossRef Sharma BK, Jain S, Suri S, Numano F (1996) Diagnostic criteria for Takayasu arteritis. Int J Cardiol 54(Suppl): S141–S147PubMedCrossRef
75.
Zurück zum Zitat Valsakumar AK, Valappil UC, Jorapur V et al (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol 30:1793–1798PubMed Valsakumar AK, Valappil UC, Jorapur V et al (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol 30:1793–1798PubMed
82.
Zurück zum Zitat Singh S, Sharma D, Suri DD et al (2016) Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India. Clin Exp Rheumatol 34:S134–S138PubMed Singh S, Sharma D, Suri DD et al (2016) Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India. Clin Exp Rheumatol 34:S134–S138PubMed
87.
Zurück zum Zitat Ringold S, Weiss PF, Beukelman T et al (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65:2499–2512. https://doi.org/10.1002/art.38092 PubMedPubMedCentralCrossRef Ringold S, Weiss PF, Beukelman T et al (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65:2499–2512. https://​doi.​org/​10.​1002/​art.​38092 PubMedPubMedCentralCrossRef
109.
Zurück zum Zitat Handa R (2014) Rheumatology in postgraduate curriculum. Indian J Rheumatol 9:127–130CrossRef Handa R (2014) Rheumatology in postgraduate curriculum. Indian J Rheumatol 9:127–130CrossRef
110.
Zurück zum Zitat Das B (2014) Rheumatology in undergraduate curriculum. Indian J Rheumatol 9:69–72CrossRef Das B (2014) Rheumatology in undergraduate curriculum. Indian J Rheumatol 9:69–72CrossRef
114.
Zurück zum Zitat Kumar A (2002) Indian guidelines on the management of SLE. J Indian Rheumatol Assoc 10:80–96 Kumar A (2002) Indian guidelines on the management of SLE. J Indian Rheumatol Assoc 10:80–96
118.
Zurück zum Zitat (2016) Indian J Rheumatol 11:S1–S108 (2016) Indian J Rheumatol 11:S1–S108
119.
Zurück zum Zitat (2017) Indian J Rheumatol 12:S1–S132 (2017) Indian J Rheumatol 12:S1–S132
Metadaten
Titel
Rheumatology science and practice in India
verfasst von
Durga Prasanna Misra
Aman Sharma
Vikas Agarwal
Publikationsdatum
19.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 9/2018
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-018-4111-4

Weitere Artikel der Ausgabe 9/2018

Rheumatology International 9/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.